OGN
Organon & Co.
NYSE · USHealthcareDrug Manufacturers - General
$13.49-0.22%
Price as of Jul 20, 2026
OGN growth
Organon & Co. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -2.1%
- EBITDA
- -7.8%
- EBIT
- -15.2%
- EPS
- -67.4%
- Free cash flow
- +2.2%
- Operating cash flow
- -9.4%
Forward estimates
- Revenue
- +0.3%
- EBITDA
- +14.8%
- EPS
- +289.7%
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -9.9%
- EBIT
- -9.0%
- Net income
- -41.1%
- EPS
- -41.6%
- Free cash flow
- +7.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.